abstract |
The present invention is in part based on the identification of the IRE1α-XBP1-cMyc axis in NK cell immunity. The present invention is a composition and method for treating a condition that may benefit from regulating (eg, upregulating or downregulating) an immune response with agents that regulate the IRE1α-XBP1 pathway. Alternatively, a composition containing modified NK cells is provided. [Selection diagram] FIG. 4B |